A Multiple Dose Study of Raltegravir (RAL) Formulations
Background: ISENTRESS (raltegravir) is an integrase strand transfer inhibitor indicated in combination with other anti-retroviral drugs for the treatment of human immunodeficiency virus (HIV-1) infection. ISENTRESS is currently marketed as a 400 mg oral compressed tablet (OCT) formulation of raltegravir given twice daily for a total daily dose of 800 mg. This study was conducted…